Food and Drug Administration approvals in phase 3 Cancer clinical trials

ADVANCEMENTS IN TUMOR IMMUNOTHERAPY AND CANCER VACCINES

228 p | 84 | 18

Chapter 012. Pain: Pathophysiology and Management (Part 6)

6 p | 79 | 5

Management of Unscheduled Bleeding in Women Using Hormonal Contraception

19 p | 53 | 4

Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial

11 p | 13 | 3

CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer

8 p | 3 | 2

Offering extended use of the contraceptive implant via an implementation science framework: A qualitative study of clinicians’ perceived barriers and facilitators

9 p | 1 | 1

Tivozanib in renal cell carcinoma: A systematic review of the evidence and its dissemination in the scientific literature

10 p | 9 | 1

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

11 p | 13 | 1

The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: A meta-analysis of clinical trials

6 p | 13 | 0